{"name":"Otsuka Holdings Co., Ltd.","slug":"otsuka","ticker":"OTSKY","exchange":"OTC","domain":"otsuka.com","description":"Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services ","hq":"Tokyo, Japan","founded":1988,"employees":"37758","ceo":"Tatsuo Higuchi","sector":"Big Pharma","stockPrice":35.12,"stockChange":-0.02,"stockChangePercent":-0.06,"marketCap":"$37.9B","metrics":{"revenue":2468892114944,"revenueGrowth":8.4,"grossMargin":71.7,"rdSpend":0,"netIncome":363149983744,"cash":534645014528,"dividendYield":1.24,"peRatio":16.3,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Rexulti","genericName":"BREXPIPRAZOLE","slug":"brexpiprazole","revenue":1400000000,"yoyGrowth":0,"percentOfTotal":53.8},{"name":"Samsca","genericName":"TOLVAPTAN","slug":"tolvaptan","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":46.2}],"timeline":[{"date":"1997-01-01","label":"Tomefloxacin first approved","drug":"Tomefloxacin","drugSlug":"grepafloxacin","type":"approval","sentiment":"positive"},{"date":"1999-01-01","label":"Pletal first approved","drug":"Pletal","drugSlug":"cilostazol","type":"approval","sentiment":"positive"},{"date":"2009-01-01","label":"Samsca first approved","drug":"Samsca","drugSlug":"tolvaptan","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Rexulti first approved","drug":"Rexulti","drugSlug":"brexpiprazole","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Inqovi first approved","drug":"Inqovi","drugSlug":"inqovi","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2025-06-01","label":"Abilify patent cliff ($1.4B at risk)","drug":"Abilify","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-01","label":"Lodine patent cliff ($200M at risk)","drug":"Lodine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":1400000000,"percentOfTotal":53.8,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Rexulti","genericName":"BREXPIPRAZOLE","slug":"brexpiprazole","indication":"Major depressive disorder","status":"marketed","revenue":1400000000}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":1200000000,"percentOfTotal":46.2,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Samsca","genericName":"TOLVAPTAN","slug":"tolvaptan","indication":"Fluid retention in heart failure","status":"marketed","revenue":1200000000}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Inqovi","genericName":"Inqovi","slug":"inqovi","indication":"Chronic myelomonocytic leukemia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Pletal","genericName":"CILOSTAZOL","slug":"cilostazol","indication":"Intermittent claudication","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Tomefloxacin","genericName":"GREPAFLOXACIN","slug":"grepafloxacin","indication":"Acute Moraxella catarrhalis bronchitis","status":"marketed"}]}],"pipeline":[{"name":"Rexulti","genericName":"BREXPIPRAZOLE","slug":"brexpiprazole","phase":"marketed","mechanism":"D(2) dopamine receptor","indications":["Major depressive disorder","Schizophrenia"],"catalyst":""},{"name":"Samsca","genericName":"TOLVAPTAN","slug":"tolvaptan","phase":"marketed","mechanism":"Samsca works by blocking the action of vasopressin, a hormone that regulates water levels in the body.","indications":["Fluid retention in heart failure","Hyponatremia","Polycystic kidney disease, adult type","Syndrome of inappropriate vasopressin secretion"],"catalyst":""},{"name":"Inqovi","genericName":"Inqovi","slug":"inqovi","phase":"marketed","mechanism":"Inqovi works by blocking the enzyme cytidine deaminase, allowing chemotherapy medications to be more effective.","indications":["Chronic myelomonocytic leukemia","Myelodysplastic syndrome"],"catalyst":""},{"name":"Pletal","genericName":"CILOSTAZOL","slug":"cilostazol","phase":"marketed","mechanism":"cGMP-inhibited 3',5'-cyclic phosphodiesterase A","indications":["Intermittent claudication"],"catalyst":""},{"name":"Tomefloxacin","genericName":"GREPAFLOXACIN","slug":"grepafloxacin","phase":"marketed","mechanism":"Potassium voltage-gated channel subfamily H member 2","indications":["Acute Moraxella catarrhalis bronchitis","Acute bacterial bronchitis","Acute gonococcal cervicitis","Chlamydia Cervicitis","Gonorrhea"],"catalyst":""}],"recentEvents":[{"date":"2024-02-01","type":"earnings","headline":"Otsuka Holdings Co., Ltd. Reports Fiscal Year 2023 Earnings","summary":"Otsuka Holdings reported a net income of ¥143.9 billion for fiscal year 2023, up 4.3% from the previous year.","drugName":"","sentiment":"positive"},{"date":"2023-06-01","type":"deal","headline":"Otsuka Holdings Partners with Biogen to Develop Alzheimer's Disease Treatment","summary":"Otsuka Holdings and Biogen announced a partnership to develop a new treatment for Alzheimer's disease, with Otsuka Holdings contributing its expertise in CNS disorders.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQNEM1b0dMdnFia3JqeUlTZ252UUtzTnFkWTZ3RGhzOFJGLVpEMWFtSlB0YzBjYnFwSTRQb3pkNHVfMG5VR0tMeE40WS1DMUF4dHJFc3p2WHhzQkxrY0VUS0prX0pIaC1XRXNIR21Ccllic1Z6Y01GcE92UFBqLWNCS0hRY3dXRVY0Y01ZeUFFNmlLWXpWY2F0YV9GMl9VSVFtLUlnSERWUQ?oc=5","date":"2026-04-08","type":"pipeline","source":"AD HOC NEWS","summary":"What you need to know for smart investing now - AD HOC NEWS","headline":"What you need to know for smart investing now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPZmw2czBYVGFYUGRPZDlERzlVdjNXdlFKMDJDeXdUdDd4Z2FBSFhxQkQwOG1OS3NNYzJHV0ZTWlRlZ29IUXFQcU5CMGlnRm1UVG13UmFuMnhIM3FkaGpGLWRLV09PNVg5eS10ME1mQjJjdjI1YmVaSDNHSXgtVzhaYkFsV1VBczkxT3gwSEljRVZialY2SW81dzRadHFOV19JcmlyeXhDd1BBSHY2X3F1S2t3?oc=5","date":"2026-03-11","type":"deal","source":"MarketBeat","summary":"Otsuka (OTCMKTS:OTSKY) Reaches New 1-Year High - Should You Buy? - MarketBeat","headline":"Otsuka (OTCMKTS:OTSKY) Reaches New 1-Year High - Should You Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQcE9aOThCZkQ5SnlPenNFT0xqZzRkOEtnTlVramJMRXBtamxTZHhZU1p4UHdBeXRKT2RTNlltcklwTjJSUVJSczd2bVpPaEtyUFBUVjBFc3JyTWRHRnFhekYtcjNZNHBELW9WcGl3bnF2OVdmRGs5blJLcTJmZUdKRVpDcGdGS3ZqeFN3ZDRHUVh3czRLczRYZGJlR1F1OUxYRFB1MnViU0VGRUk?oc=5","date":"2026-03-10","type":"pipeline","source":"MarketBeat","summary":"Otsuka (OTCMKTS:OTSKY) Trading Up 8.6% - Here's What Happened - MarketBeat","headline":"Otsuka (OTCMKTS:OTSKY) Trading Up 8.6% - Here's What Happened","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQMmRrQ1QzckhTZks0SjE4NTBQN2hfc1B3VklRVmRpcklqZ3lIYVM2ejNyUVpMUDZCWjBJd3UtVzZnWjltZ0VISzNQbUwzNjJsVnRpRFRPRWZDN05iUkM0blQtZEtZS0M2Z3hkbWduM1pFemtuNjFYd1lRWFd0UEVCQnIxUHpoWEtMcWV0cl9BX25pckcwZkVnQWZIWnNtMmxNWngxZE1qdFI1Zw?oc=5","date":"2026-02-19","type":"earnings","source":"Seeking Alpha","summary":"Otsuka Holdings Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation (OTCMKTS:OTSKY) 2026-02-19 - Seeking Alpha","headline":"Otsuka Holdings Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation (OTCMKTS:OTSKY) 2026-02-19","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPeHBjc1dfYUJyVm1hRTBSZ0FKbURncTR2VFBfZVdFYzBWbExaVjFnaWFIcEdCbG9kRWhVRTh6eGlFQ1hjS0NQZkdoUFpzdUxaNTNZTlhqRUdENjRiNllHOEQzVnJDNWZmN1JlSHlobkFORHdvd2ZvOEJtS0Mwa3l6ckRFLWFnaVkyTVJUamFEdlV2cXJFUVQ1WGswY0ZlQ3RWTm5sSktCVzMxNVBGdXNkWEZYVEFLTkR3V0VZYjAxVnFkdHEzOGVnRlpaWTZnRUtxSkR0QTZRNA?oc=5","date":"2025-10-16","type":"pipeline","source":"Sahm","summary":"Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market - Sahm","headline":"Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNZjNIUkpPb0JyZGZxQW80WmVoYVlYNjlSVWsxRi1sNUttUlRUNWFqc1B6VjluN0NFUXZKVGtIQkZZYUVnamZGeXpSOTVPRlpPWF9qdDd1d2xCaVU2Q1c1cUw0Z1k3S2Q5LU5VQU1DZkx2TXRKblpvRU53dDdfQVBrV0FpS0FNZjV5OUlKdA?oc=5","date":"2025-06-29","type":"regulatory","source":"RTTNews","summary":"Biotech Stocks Facing FDA Decision In July 2025 - RTTNews","headline":"Biotech Stocks Facing FDA Decision In July 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQLTFreHp4X0pmRTIzM2ZIWVoyNWM5U2JCeFhZY1czMnY5RDNteklSTUVRMjZhWU0yM3ZMTVp3a3NKQmhXQ0Riakk0NUJ3eV9zblMtWU9xeHZGU1c5LXdUR2JiaDI0NkxBN25wS2ZGT18xZXlwZ3Ita3dCMkk1Yzd4ZmdaZw?oc=5","date":"2025-06-06","type":"pipeline","source":"Seeking Alpha","summary":"Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha","headline":"Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBmQ2Nlai1yU2pWc2N6YXNJdzVlZDQ4V1R6a1NRMzN1cE8tNlJYVnQxQjdlX19kQmxZVHZyWHV2SkhWOXI3RjRiREtRdGRmY1NGZHJXblNRR0NKaTB6cTd4MGdETkVoRnM?oc=5","date":"2017-05-29","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Haw Par Corporation Limited (H02.SI) balance sheet - Yahoo Finance Singapore","headline":"Haw Par Corporation Limited (H02.SI) balance sheet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1kY0N3MDRKZExZYms4SDRlNlZUWTR0VUpXLUxyZHR3dkpYZmhWMUEwNGZud3RiSlBFcDFNVU1SemtsZFZuaUFCcEdDUHQwS3lxTFBB?oc=5","date":"2017-05-17","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Otsuka Holdings Co., Ltd. (OTSKY) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Otsuka Holdings Co., Ltd. (OTSKY) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Abilify","drugSlug":"aripiprazole","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Lodine","drugSlug":"etodolac","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":200000000}],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Takeda Pharmaceutical Co., Ltd.","Eisai Co., Ltd.","Mitsubishi Tanabe Pharma Corporation"],"therapeuticFocus":["Central Nervous System (CNS) Disorders","Oncology","Nephrology"],"financials":null,"yahoo":{"currentPrice":35.12,"previousClose":35.14,"fiftyTwoWeekHigh":36.55,"fiftyTwoWeekLow":21.64,"fiftyTwoWeekRange":"21.64 - 36.55","fiftyDayAverage":32.88,"twoHundredDayAverage":28.36,"beta":-0.08,"enterpriseValue":-221805019136,"forwardPE":21.7,"priceToBook":0.97,"priceToSales":0.02,"enterpriseToRevenue":-0.09,"enterpriseToEbitda":-0.38,"pegRatio":0,"ebitda":589933969408,"ebitdaMargin":23.9,"freeCashflow":191032754176,"operatingCashflow":403579011072,"totalDebt":227975004160,"debtToEquity":7.4,"currentRatio":2.17,"returnOnAssets":7.5,"returnOnEquity":12.5,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":40,"targetHighPrice":40,"targetLowPrice":40,"dividendRate":0.44,"payoutRatio":0.1,"fiveYearAvgDividendYield":1.93,"exDividendDate":1751241600,"insiderHeldPercent":0,"institutionHeldPercent":0.3,"sharesOutstanding":1055972498,"floatShares":441623451,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":2.15,"epsForward":1.62,"revenuePerShare":2328.71,"bookValue":36.22,"officers":[{"age":67,"name":"Mr. Makoto  Inoue","title":"President, CEO & Representative Director"},{"age":64,"name":"Ms. Yuko  Makino","title":"CFO & Executive Director"},{"age":61,"name":"Ms. Noriko  Tojo","title":"Executive Director"},{"age":65,"name":"Mr. Yoshiro  Matsuo","title":"Executive Deputy President & Representative Director"},{"age":59,"name":"Mr. Masayuki  Kobayashi","title":"Executive Director"},{"age":59,"name":"Mr. Shuichi  Takagi","title":"Executive Director"},{"age":null,"name":"Tomohiro  Emura Ph.D.","title":"Executive VP & Operating Officer of IR, Public Relations, and Sustainability Promotion"},{"age":null,"name":"Chiaki  Sakurai","title":"Senior EVP, Operating Officer & Dir. of Nutraceutical Bus., Global Strat. and Planning Headquarters"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.otsuka.com/en/ir/","website":"https://www.otsuka.com","phone":""}}